2 results
Approved WMOCompleted
To determine the relative bioavailability of pramipexole 4.5 mg tablets vs. 4.5 mg Sifrol in healthy subjects after up-titration.
DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A.
Primary objectives:To assess the proportion of non-severe hemophilia A patients within FVIII target levels with the DDAVP and FVIII concentrate combination treatment in the first 72 hours after the start of combination treatment, without adding off-…